August 17, 2016 / 2:37 PM / 2 years ago

BUZZ-Aurinia Pharmaceuticals: H.C. Wainwright raises PT

** Canadian drug developer’s U.S.-listed shares up 10 pct at $2.54, moving back into the black for the year

** H.C. Wainwright raises PT on stock to $10 from $7 vs. analysts’ median PT of $9

** Aurinia said Monday its experimental lead drug, which treats lupus nephritis passed a mid-stage study; it also reported 13 trial deaths, which it says were all deemed unrelated to the drug

** Company’s stock tanked about 56 pct on Monday and bounced nearly 28 pct on Tuesday

** H.C. Wainwright believes Aurinia will initiate a late-stage study of the drug, which it says still retains an overall profile that is very likely “approvable”, despite the Street’s overriding concern with the patient deaths

** Following the swings in its stock over the past few days, including Wednesday’s gain, the shares are up 3 pct this year

** Lupus nephritis (LN) is a life-threatening condition that develops in up to 60 pct of patients with lupus, in which the body’s immune system attacks itself

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below